Adjuvant chemotherapy versus surgery alone for esophageal squamous cell carcinoma: A meta-analysis of randomized controlled trials and nonrandomized studies

Diseases of the Esophagus

Volumn 27, Issue 6, 2014, Pages 574-584

  Zhang, S S ^a   Yang, H ^a   Xie, X ^a   Luo, K J ^a   Wen, J ^a   Bella, A E ^a   Hu, Y ^a   Yang, F ^a   Fu, J H ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Adjuvant; Chemotherapy; Esophageal neoplasm; Meta analysis; Survival

Indexed keywords

CISPLATIN; FLUOROURACIL; TEGAFUR; URACIL; VINDESINE; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; ESOPHAGUS CARCINOMA; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SQUAMOUS CELL CARCINOMA; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; ESOPHAGUS RESECTION; LYMPH NODE METASTASIS; MORTALITY; PATHOLOGY; SECONDARY; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; VINDESINE;

EID: 84904913904     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/dote.12073     Document Type: Article

References (37)

1. Rice T W, Rusch V W, Apperson-Hansen C etal. Worldwide esophageal cancer collaboration. Dis Esophagus 2009; 22: 1-8.
2. Allum W H, Stenning S P, Bancewicz J etal. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009; 27: 5062-5067.
3. Pouliquen X, Levard H, Hay J M etal. 5-Fluorouracil and cisplatin therapy after palliative surgical resection of squamous cell carcinoma of the esophagus. A multicenter randomized trial. French Associations for Surgical Research. Ann Surg 1996; 223: 127-133.
4. Ando N, Iizuka T, Kakegawa T etal. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 1997; 114: 205-209.
5. Ando N, Iizuka T, Ide H etal. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol 2003; 21: 4592-4596.
6. Malthaner R A, Wong R K, Rumble R B etal. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2004; 2: 35-52.
7. Zhang J, Chen H Q, Zhang Y H etal. Adjuvant chemotherapy in oesophageal cancer a meta-analysis and experience from the Shanghai Cancer Hospital. J Int Med Res 2008; 36: 875-882.
8. Shiozaki A Y H, Itoi H etal. Long-term administration of low-dose cisplatin plus 5-fluorouracil prolongs the postoperative survival of patients with esophageal cancer. Oncol Rep 2004; 13: 667-672.
9. Zhu S, Su J, Li J etal. Survival study of adjuvant radiotherapy and chemotherapy after definitive surgery of locally advanced esophageal carcinoma. Int J Radiat Oncol Biol Phys 2011; 81: 323.
10. Ando N, Kato H, Igaki H etal. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 2012; 19: 68-74.
11. Ajani J A, Swisher S G. Preoperative chemotherapy for localized squamous cell carcinoma of the esophagus? We should go back to the drawing board! Ann Surg Oncol 2012; 19: 3-4.
12. Kitagawa Y, Ando N, Nakamura K etal. The role of adjuvant chemotherapy for localized squamous cell esophageal cancer: current Japanese standard and the unending role of the drawing board. Ann Surg Oncol 2012; 19: 1425-1427.
13. Jadad A R, Moore R, Carroll D etal. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
14. Kjaergard L L, Villumsen J, Gluud C: Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001; 135: 982-989.
15. Moher D, Pham B, Jones A etal. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-613.
16. Stroup D F, Berlin J, Morton S C etal. Meta-analysis of observational studies in epidemiology. JAMA 2000; 283: 2008-2012.
17. Slim K, Nini E, Forestier D etal. Methodological index for non-randomized studies (MINORS) development and validation of a new instrument. ANZ J Surg 2003; 73: 712-716.
18. Kellum J A, Angus D C, Johnson J P etal. Continuous versus intermittent renal replacement therapy: a meta-analysis. Intensive Care Med 2002; 28: 29-37.
19. Vinuela E F, Gonen M, Brennan M F etal. Laparoscopic versus open distal gastrectomy for gastric cancer: a meta-analysis of randomized controlled trials and high-quality nonrandomized studies. Ann Surg 2012; 255: 446-456.
20. Parmer M, Torri V, Stewart L: Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 2815-2834.
21. Tierney J F, Stewart L A, Ghersi D etal. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; 8: 16-32.
22. Lee J, Lee K E, Im Y H etal. Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma. Ann Thorac Surg 2005; 80: 1170-1175.
23. Fang W, Chen W, Lin Q etal. Extensive lymph node dissection combined with postoperative chemotherapy for thoracic esophageal carcinama. Tumor 2001; 21: 460-462.
24. Heroor A, Fujita H, Sueyoshi S etal. Adjuvant chemotherapy after radical resection of squamous cell carcinoma in the thoracic esophagus: who benefits? A retrospective study. Dig Surg 2003; 20: 229-235; discussion 236-7.
25. Liu J, Wang Y K, Liu Y etal. The effect of postoperative chemotherapy after esophageactomy on the survival rate to patients with original squamous cell carcinoma of esophagus. Zhonghua Liu Xing Bing Xue Za Zhi 2004; 25: 346-350.
26. Zhang J, Zhang Y W, Chen Z W etal. Adjuvant chemotherapy of cisplatin, 5-fluorouracil and leucovorin for complete resectable esophageal cancer: a case-matched cohort study in east China. Dis Esophagus 2008; 21: 207-213.
27. Yamamoto S, Ozawa S, Shimada H etal. Effectiveness of adjuvant chemotherapy for surgical patients with clinical stage II/III thoracic esophageal cancer. Dis Esophagus 2010; 23 (Suppl): 34A.
28. Armanios M, Xu R, Forastiere A A etal. Adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastro-esophageal junction, and cardia: phase II trial (E8296) of the Eastern Cooperative Oncology Group. J Clin Oncol 2004; 22: 4495-4499.
29. Cancer. IUA: TNM Classification of Malignant Tumors. Fifth fully revised edition. New York: Springer-Verlag, 1997.
30. MacLehose R R, Reeves B, Harvey I M etal. A systematic review of comparisons of effect sizes derived from randomised and non-randomised studies. Health Technol Assess 2000; 4: 1-154.
31. Abraham N S, Byrne C J, Young J M etal. Meta-analysis of well-designed nonrandomized comparative studies of surgical procedures is as good as randomized controlled trials. J Clin Epidemiol 2010; 63: 238-245.
32. Shimada Y, Watanabe G, Yamasaki S etal. Histological response of cisplatin predicts patients'survival in oesophageal cancer and p53 protein accumulation in pretreatment biopsy is associated with cisplatin sensitivity. Eur J Cancer 2000; 36: 987-993.
33. Akiyama H, Tsurumaru M, Udagawa H etal. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 1994; 220: 364-372;discussion 372-3.
34. Kato H, Watanabe H, Tachimori Y etal. Evaluation of neck lymph node dissection for thoracic esophageal carcinoma. Ann Thorac Surg 1991; 51: 931-935.
35. Baba M, Aikou T, Yoshinaka H, Natsugoe S etal. Long-term results of subtotal esophagectomy with three-field lymphadenectomy for carcinoma of the thoracic esophagus. Ann Surg 1994; 219: 310-316.
36. Fujita H, Sueyoshi S, Tanaka T etal. Optimal lymphadenectomy for squamous cell carcinoma in the thoracic esophagus: comparing the short- and long-term outcome among the four types of lymphadenectomy. World J Surg 2003; 27: 571-579.
37. Schwarz R E, Smith D D. Clinical impact of lymphadenectomy extent in resectable esophageal cancer. J Gastrointest Surg 2007; 11: 1384-1393; discussion 1393-4.